nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—prostate cancer	0.239	1	CbGaD
Pimecrolimus—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0739	0.207	CbGbCtD
Pimecrolimus—CYP3A4—Bicalutamide—prostate cancer	0.0388	0.109	CbGbCtD
Pimecrolimus—CYP3A4—Estramustine—prostate cancer	0.0361	0.101	CbGbCtD
Pimecrolimus—CYP3A4—Abiraterone—prostate cancer	0.0322	0.09	CbGbCtD
Pimecrolimus—CYP3A4—Flutamide—prostate cancer	0.0322	0.09	CbGbCtD
Pimecrolimus—CYP3A4—Cabazitaxel—prostate cancer	0.0238	0.0666	CbGbCtD
Pimecrolimus—CYP3A4—Estrone—prostate cancer	0.0233	0.0651	CbGbCtD
Pimecrolimus—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0207	0.058	CbGbCtD
Pimecrolimus—CYP3A4—Conjugated Estrogens—prostate cancer	0.0152	0.0426	CbGbCtD
Pimecrolimus—CYP3A4—Mitoxantrone—prostate cancer	0.0138	0.0387	CbGbCtD
Pimecrolimus—CYP3A4—Estradiol—prostate cancer	0.0134	0.0374	CbGbCtD
Pimecrolimus—CYP3A4—Prednisone—prostate cancer	0.0115	0.0321	CbGbCtD
Pimecrolimus—CYP3A4—Etoposide—prostate cancer	0.00873	0.0244	CbGbCtD
Pimecrolimus—CYP3A4—Docetaxel—prostate cancer	0.00798	0.0223	CbGbCtD
Pimecrolimus—CYP3A4—Doxorubicin—prostate cancer	0.00595	0.0166	CbGbCtD
Pimecrolimus—MTOR—prostate gland—prostate cancer	0.00419	0.0976	CbGeAlD
Pimecrolimus—FKBP1A—prostate gland—prostate cancer	0.00377	0.0878	CbGeAlD
Pimecrolimus—MTOR—seminal vesicle—prostate cancer	0.00354	0.0826	CbGeAlD
Pimecrolimus—CYP3A4—urine—prostate cancer	0.00343	0.0799	CbGeAlD
Pimecrolimus—FKBP1A—seminal vesicle—prostate cancer	0.00319	0.0743	CbGeAlD
Pimecrolimus—MTOR—epithelium—prostate cancer	0.00308	0.0718	CbGeAlD
Pimecrolimus—MTOR—renal system—prostate cancer	0.00286	0.0666	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—prostate cancer	0.00277	0.0645	CbGeAlD
Pimecrolimus—FKBP1A—renal system—prostate cancer	0.00257	0.0599	CbGeAlD
Pimecrolimus—FKBP1A—urethra—prostate cancer	0.00252	0.0588	CbGeAlD
Pimecrolimus—Tacrolimus—PPP3CA—prostate cancer	0.00238	0.386	CrCbGaD
Pimecrolimus—MTOR—bone marrow—prostate cancer	0.00216	0.0503	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—prostate cancer	0.00194	0.0453	CbGeAlD
Pimecrolimus—MTOR—testis—prostate cancer	0.00185	0.043	CbGeAlD
Pimecrolimus—FKBP1A—testis—prostate cancer	0.00166	0.0387	CbGeAlD
Pimecrolimus—MTOR—lymph node—prostate cancer	0.00134	0.0312	CbGeAlD
Pimecrolimus—Sirolimus—FGF2—prostate cancer	0.00125	0.203	CrCbGaD
Pimecrolimus—FKBP1A—lymph node—prostate cancer	0.0012	0.028	CbGeAlD
Pimecrolimus—CYP3A4—renal system—prostate cancer	0.000839	0.0196	CbGeAlD
Pimecrolimus—Temsirolimus—CYP3A5—prostate cancer	0.000552	0.0895	CrCbGaD
Pimecrolimus—Sirolimus—CYP3A5—prostate cancer	0.000486	0.0788	CrCbGaD
Pimecrolimus—Tacrolimus—CYP3A5—prostate cancer	0.000486	0.0788	CrCbGaD
Pimecrolimus—Everolimus—CYP3A4—prostate cancer	0.000354	0.0574	CrCbGaD
Pimecrolimus—Temsirolimus—CYP3A4—prostate cancer	0.000239	0.0387	CrCbGaD
Pimecrolimus—Sirolimus—CYP3A4—prostate cancer	0.00021	0.0341	CrCbGaD
Pimecrolimus—Tacrolimus—CYP3A4—prostate cancer	0.00021	0.0341	CrCbGaD
Pimecrolimus—Eye disorder—Docetaxel—prostate cancer	0.000112	0.000585	CcSEcCtD
Pimecrolimus—Flushing—Docetaxel—prostate cancer	0.000111	0.000581	CcSEcCtD
Pimecrolimus—Paraesthesia—Mitoxantrone—prostate cancer	0.000111	0.000578	CcSEcCtD
Pimecrolimus—Dyspnoea—Mitoxantrone—prostate cancer	0.00011	0.000574	CcSEcCtD
Pimecrolimus—Cough—Etoposide—prostate cancer	0.00011	0.000572	CcSEcCtD
Pimecrolimus—Eye disorder—Capecitabine—prostate cancer	0.000109	0.000566	CcSEcCtD
Pimecrolimus—Immune system disorder—Docetaxel—prostate cancer	0.000108	0.000565	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Estradiol—prostate cancer	0.000108	0.000565	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Docetaxel—prostate cancer	0.000108	0.000564	CcSEcCtD
Pimecrolimus—Flushing—Capecitabine—prostate cancer	0.000108	0.000562	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Epirubicin—prostate cancer	0.000107	0.000557	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000106	0.000554	CcSEcCtD
Pimecrolimus—Vomiting—Goserelin—prostate cancer	0.000106	0.000554	CcSEcCtD
Pimecrolimus—Breast disorder—Epirubicin—prostate cancer	0.000106	0.000552	CcSEcCtD
Pimecrolimus—Constipation—Mitoxantrone—prostate cancer	0.000105	0.00055	CcSEcCtD
Pimecrolimus—Pain—Mitoxantrone—prostate cancer	0.000105	0.00055	CcSEcCtD
Pimecrolimus—Rash—Goserelin—prostate cancer	0.000105	0.000549	CcSEcCtD
Pimecrolimus—Dermatitis—Goserelin—prostate cancer	0.000105	0.000549	CcSEcCtD
Pimecrolimus—Vomiting—Conjugated Estrogens—prostate cancer	0.000105	0.000549	CcSEcCtD
Pimecrolimus—Urticaria—Estradiol—prostate cancer	0.000105	0.000549	CcSEcCtD
Pimecrolimus—Immune system disorder—Capecitabine—prostate cancer	0.000105	0.000547	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Capecitabine—prostate cancer	0.000105	0.000546	CcSEcCtD
Pimecrolimus—Body temperature increased—Estradiol—prostate cancer	0.000105	0.000546	CcSEcCtD
Pimecrolimus—Abdominal pain—Estradiol—prostate cancer	0.000105	0.000546	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Epirubicin—prostate cancer	0.000105	0.000546	CcSEcCtD
Pimecrolimus—Headache—Goserelin—prostate cancer	0.000105	0.000546	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—prostate cancer	0.000104	0.000545	CcSEcCtD
Pimecrolimus—Erythema—Docetaxel—prostate cancer	0.000104	0.000545	CcSEcCtD
Pimecrolimus—Malnutrition—Docetaxel—prostate cancer	0.000104	0.000545	CcSEcCtD
Pimecrolimus—Rash—Conjugated Estrogens—prostate cancer	0.000104	0.000544	CcSEcCtD
Pimecrolimus—Dermatitis—Conjugated Estrogens—prostate cancer	0.000104	0.000543	CcSEcCtD
Pimecrolimus—Headache—Conjugated Estrogens—prostate cancer	0.000104	0.00054	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Etoposide—prostate cancer	0.000103	0.000535	CcSEcCtD
Pimecrolimus—Infection—Etoposide—prostate cancer	0.000102	0.000532	CcSEcCtD
Pimecrolimus—Erythema—Capecitabine—prostate cancer	0.000101	0.000528	CcSEcCtD
Pimecrolimus—Malnutrition—Capecitabine—prostate cancer	0.000101	0.000528	CcSEcCtD
Pimecrolimus—Asthma—Epirubicin—prostate cancer	0.000101	0.000528	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—prostate cancer	0.000101	0.000528	CcSEcCtD
Pimecrolimus—Back pain—Docetaxel—prostate cancer	0.000101	0.000527	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000101	0.000526	CcSEcCtD
Pimecrolimus—Skin disorder—Etoposide—prostate cancer	9.96e-05	0.00052	CcSEcCtD
Pimecrolimus—Nausea—Goserelin—prostate cancer	9.91e-05	0.000517	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—prostate cancer	9.88e-05	0.000516	CcSEcCtD
Pimecrolimus—Nausea—Conjugated Estrogens—prostate cancer	9.82e-05	0.000512	CcSEcCtD
Pimecrolimus—Urticaria—Mitoxantrone—prostate cancer	9.79e-05	0.000511	CcSEcCtD
Pimecrolimus—Back pain—Capecitabine—prostate cancer	9.78e-05	0.00051	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—prostate cancer	9.78e-05	0.00051	CcSEcCtD
Pimecrolimus—Hypersensitivity—Estradiol—prostate cancer	9.75e-05	0.000509	CcSEcCtD
Pimecrolimus—Body temperature increased—Mitoxantrone—prostate cancer	9.75e-05	0.000509	CcSEcCtD
Pimecrolimus—Abdominal pain—Mitoxantrone—prostate cancer	9.75e-05	0.000509	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—prostate cancer	9.72e-05	0.000507	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—prostate cancer	9.68e-05	0.000505	CcSEcCtD
Pimecrolimus—Eye disorder—Prednisone—prostate cancer	9.67e-05	0.000505	CcSEcCtD
Pimecrolimus—Flushing—Prednisone—prostate cancer	9.6e-05	0.000501	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—prostate cancer	9.39e-05	0.00049	CcSEcCtD
Pimecrolimus—Pruritus—Estradiol—prostate cancer	9.36e-05	0.000489	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—prostate cancer	9.35e-05	0.000488	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—prostate cancer	9.35e-05	0.000488	CcSEcCtD
Pimecrolimus—Immune system disorder—Prednisone—prostate cancer	9.34e-05	0.000488	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—prostate cancer	9.23e-05	0.000481	CcSEcCtD
Pimecrolimus—Paraesthesia—Etoposide—prostate cancer	9.21e-05	0.000481	CcSEcCtD
Pimecrolimus—Dyspnoea—Etoposide—prostate cancer	9.14e-05	0.000477	CcSEcCtD
Pimecrolimus—Cough—Docetaxel—prostate cancer	9.11e-05	0.000476	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mitoxantrone—prostate cancer	9.08e-05	0.000474	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—prostate cancer	9.06e-05	0.000473	CcSEcCtD
Pimecrolimus—Diarrhoea—Estradiol—prostate cancer	9.05e-05	0.000472	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—prostate cancer	9.01e-05	0.00047	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—prostate cancer	9.01e-05	0.00047	CcSEcCtD
Pimecrolimus—Malnutrition—Prednisone—prostate cancer	9.01e-05	0.00047	CcSEcCtD
Pimecrolimus—Erythema—Prednisone—prostate cancer	9.01e-05	0.00047	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—prostate cancer	8.99e-05	0.000469	CcSEcCtD
Pimecrolimus—Arthralgia—Docetaxel—prostate cancer	8.89e-05	0.000464	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Etoposide—prostate cancer	8.85e-05	0.000462	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	8.83e-05	0.000461	CcSEcCtD
Pimecrolimus—Cough—Capecitabine—prostate cancer	8.82e-05	0.00046	CcSEcCtD
Pimecrolimus—Constipation—Etoposide—prostate cancer	8.77e-05	0.000458	CcSEcCtD
Pimecrolimus—Pain—Etoposide—prostate cancer	8.77e-05	0.000458	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—prostate cancer	8.76e-05	0.000457	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—prostate cancer	8.69e-05	0.000454	CcSEcCtD
Pimecrolimus—Arthralgia—Capecitabine—prostate cancer	8.61e-05	0.000449	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	8.55e-05	0.000446	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—prostate cancer	8.54e-05	0.000446	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Docetaxel—prostate cancer	8.52e-05	0.000445	CcSEcCtD
Pimecrolimus—Oedema—Docetaxel—prostate cancer	8.52e-05	0.000445	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—prostate cancer	8.5e-05	0.000444	CcSEcCtD
Pimecrolimus—Infection—Docetaxel—prostate cancer	8.47e-05	0.000442	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—prostate cancer	8.46e-05	0.000441	CcSEcCtD
Pimecrolimus—Diarrhoea—Mitoxantrone—prostate cancer	8.43e-05	0.00044	CcSEcCtD
Pimecrolimus—Vomiting—Estradiol—prostate cancer	8.41e-05	0.000439	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—prostate cancer	8.39e-05	0.000438	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Etoposide—prostate cancer	8.39e-05	0.000438	CcSEcCtD
Pimecrolimus—Nervous system disorder—Docetaxel—prostate cancer	8.36e-05	0.000436	CcSEcCtD
Pimecrolimus—Rash—Estradiol—prostate cancer	8.34e-05	0.000435	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—prostate cancer	8.34e-05	0.000435	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—prostate cancer	8.34e-05	0.000435	CcSEcCtD
Pimecrolimus—Dermatitis—Estradiol—prostate cancer	8.33e-05	0.000435	CcSEcCtD
Pimecrolimus—Headache—Estradiol—prostate cancer	8.29e-05	0.000433	CcSEcCtD
Pimecrolimus—Skin disorder—Docetaxel—prostate cancer	8.28e-05	0.000432	CcSEcCtD
Pimecrolimus—Oedema—Capecitabine—prostate cancer	8.25e-05	0.000431	CcSEcCtD
Pimecrolimus—Angioedema—Prednisone—prostate cancer	8.23e-05	0.000429	CcSEcCtD
Pimecrolimus—Infection—Capecitabine—prostate cancer	8.2e-05	0.000428	CcSEcCtD
Pimecrolimus—Urticaria—Etoposide—prostate cancer	8.15e-05	0.000425	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—prostate cancer	8.11e-05	0.000423	CcSEcCtD
Pimecrolimus—Abdominal pain—Etoposide—prostate cancer	8.11e-05	0.000423	CcSEcCtD
Pimecrolimus—Body temperature increased—Etoposide—prostate cancer	8.11e-05	0.000423	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—prostate cancer	8.11e-05	0.000423	CcSEcCtD
Pimecrolimus—Nervous system disorder—Capecitabine—prostate cancer	8.09e-05	0.000422	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—prostate cancer	8.03e-05	0.000419	CcSEcCtD
Pimecrolimus—Skin disorder—Capecitabine—prostate cancer	8.01e-05	0.000418	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—prostate cancer	7.87e-05	0.00041	CcSEcCtD
Pimecrolimus—Nausea—Estradiol—prostate cancer	7.86e-05	0.00041	CcSEcCtD
Pimecrolimus—Vomiting—Mitoxantrone—prostate cancer	7.84e-05	0.000409	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—prostate cancer	7.82e-05	0.000408	CcSEcCtD
Pimecrolimus—Rash—Mitoxantrone—prostate cancer	7.77e-05	0.000406	CcSEcCtD
Pimecrolimus—Dermatitis—Mitoxantrone—prostate cancer	7.77e-05	0.000405	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.76e-05	0.000405	CcSEcCtD
Pimecrolimus—Headache—Mitoxantrone—prostate cancer	7.72e-05	0.000403	CcSEcCtD
Pimecrolimus—Arthralgia—Prednisone—prostate cancer	7.67e-05	0.0004	CcSEcCtD
Pimecrolimus—Paraesthesia—Docetaxel—prostate cancer	7.65e-05	0.000399	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.61e-05	0.000397	CcSEcCtD
Pimecrolimus—Dyspnoea—Docetaxel—prostate cancer	7.6e-05	0.000396	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—prostate cancer	7.56e-05	0.000395	CcSEcCtD
Pimecrolimus—Hypersensitivity—Etoposide—prostate cancer	7.56e-05	0.000394	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.52e-05	0.000392	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—prostate cancer	7.51e-05	0.000392	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—prostate cancer	7.51e-05	0.000392	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—prostate cancer	7.43e-05	0.000388	CcSEcCtD
Pimecrolimus—Paraesthesia—Capecitabine—prostate cancer	7.41e-05	0.000387	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Docetaxel—prostate cancer	7.36e-05	0.000384	CcSEcCtD
Pimecrolimus—Dyspnoea—Capecitabine—prostate cancer	7.36e-05	0.000384	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisone—prostate cancer	7.35e-05	0.000384	CcSEcCtD
Pimecrolimus—Oedema—Prednisone—prostate cancer	7.35e-05	0.000384	CcSEcCtD
Pimecrolimus—Nausea—Mitoxantrone—prostate cancer	7.32e-05	0.000382	CcSEcCtD
Pimecrolimus—Immune system disorder—Epirubicin—prostate cancer	7.31e-05	0.000381	CcSEcCtD
Pimecrolimus—Infection—Prednisone—prostate cancer	7.3e-05	0.000381	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—prostate cancer	7.29e-05	0.000381	CcSEcCtD
Pimecrolimus—Constipation—Docetaxel—prostate cancer	7.29e-05	0.00038	CcSEcCtD
Pimecrolimus—Pain—Docetaxel—prostate cancer	7.29e-05	0.00038	CcSEcCtD
Pimecrolimus—Pruritus—Etoposide—prostate cancer	7.25e-05	0.000379	CcSEcCtD
Pimecrolimus—Nervous system disorder—Prednisone—prostate cancer	7.21e-05	0.000376	CcSEcCtD
Pimecrolimus—Skin disorder—Prednisone—prostate cancer	7.14e-05	0.000373	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Capecitabine—prostate cancer	7.12e-05	0.000372	CcSEcCtD
Pimecrolimus—Constipation—Capecitabine—prostate cancer	7.06e-05	0.000368	CcSEcCtD
Pimecrolimus—Pain—Capecitabine—prostate cancer	7.06e-05	0.000368	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—prostate cancer	7.04e-05	0.000368	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—prostate cancer	7.04e-05	0.000368	CcSEcCtD
Pimecrolimus—Diarrhoea—Etoposide—prostate cancer	7.02e-05	0.000366	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—prostate cancer	7e-05	0.000365	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Docetaxel—prostate cancer	6.97e-05	0.000364	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—prostate cancer	6.95e-05	0.000363	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—prostate cancer	6.81e-05	0.000356	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—prostate cancer	6.76e-05	0.000353	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Capecitabine—prostate cancer	6.75e-05	0.000352	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—prostate cancer	6.75e-05	0.000352	CcSEcCtD
Pimecrolimus—Abdominal pain—Docetaxel—prostate cancer	6.74e-05	0.000352	CcSEcCtD
Pimecrolimus—Body temperature increased—Docetaxel—prostate cancer	6.74e-05	0.000352	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Prednisone—prostate cancer	6.7e-05	0.000349	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisone—prostate cancer	6.6e-05	0.000344	CcSEcCtD
Pimecrolimus—Urticaria—Capecitabine—prostate cancer	6.55e-05	0.000342	CcSEcCtD
Pimecrolimus—Body temperature increased—Capecitabine—prostate cancer	6.52e-05	0.00034	CcSEcCtD
Pimecrolimus—Abdominal pain—Capecitabine—prostate cancer	6.52e-05	0.00034	CcSEcCtD
Pimecrolimus—Vomiting—Etoposide—prostate cancer	6.52e-05	0.00034	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—prostate cancer	6.52e-05	0.00034	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—prostate cancer	6.52e-05	0.00034	CcSEcCtD
Pimecrolimus—Rash—Etoposide—prostate cancer	6.47e-05	0.000337	CcSEcCtD
Pimecrolimus—Dermatitis—Etoposide—prostate cancer	6.46e-05	0.000337	CcSEcCtD
Pimecrolimus—Headache—Etoposide—prostate cancer	6.42e-05	0.000335	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—prostate cancer	6.3e-05	0.000329	CcSEcCtD
Pimecrolimus—Constipation—Prednisone—prostate cancer	6.28e-05	0.000328	CcSEcCtD
Pimecrolimus—Hypersensitivity—Docetaxel—prostate cancer	6.28e-05	0.000328	CcSEcCtD
Pimecrolimus—Cough—Epirubicin—prostate cancer	6.15e-05	0.000321	CcSEcCtD
Pimecrolimus—Nausea—Etoposide—prostate cancer	6.09e-05	0.000318	CcSEcCtD
Pimecrolimus—Hypersensitivity—Capecitabine—prostate cancer	6.08e-05	0.000317	CcSEcCtD
Pimecrolimus—Pruritus—Docetaxel—prostate cancer	6.03e-05	0.000315	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Prednisone—prostate cancer	6.01e-05	0.000314	CcSEcCtD
Pimecrolimus—Arthralgia—Epirubicin—prostate cancer	6e-05	0.000313	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.95e-05	0.000311	CcSEcCtD
Pimecrolimus—Urticaria—Prednisone—prostate cancer	5.84e-05	0.000305	CcSEcCtD
Pimecrolimus—Pruritus—Capecitabine—prostate cancer	5.84e-05	0.000305	CcSEcCtD
Pimecrolimus—Diarrhoea—Docetaxel—prostate cancer	5.83e-05	0.000304	CcSEcCtD
Pimecrolimus—Abdominal pain—Prednisone—prostate cancer	5.81e-05	0.000303	CcSEcCtD
Pimecrolimus—Body temperature increased—Prednisone—prostate cancer	5.81e-05	0.000303	CcSEcCtD
Pimecrolimus—Oedema—Epirubicin—prostate cancer	5.75e-05	0.0003	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—prostate cancer	5.75e-05	0.0003	CcSEcCtD
Pimecrolimus—Infection—Epirubicin—prostate cancer	5.71e-05	0.000298	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—prostate cancer	5.69e-05	0.000297	CcSEcCtD
Pimecrolimus—Diarrhoea—Capecitabine—prostate cancer	5.65e-05	0.000295	CcSEcCtD
Pimecrolimus—Nervous system disorder—Epirubicin—prostate cancer	5.64e-05	0.000294	CcSEcCtD
Pimecrolimus—Skin disorder—Epirubicin—prostate cancer	5.58e-05	0.000291	CcSEcCtD
Pimecrolimus—Arthralgia—Doxorubicin—prostate cancer	5.55e-05	0.00029	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.51e-05	0.000288	CcSEcCtD
Pimecrolimus—Vomiting—Docetaxel—prostate cancer	5.42e-05	0.000283	CcSEcCtD
Pimecrolimus—Hypersensitivity—Prednisone—prostate cancer	5.41e-05	0.000283	CcSEcCtD
Pimecrolimus—Rash—Docetaxel—prostate cancer	5.37e-05	0.00028	CcSEcCtD
Pimecrolimus—Dermatitis—Docetaxel—prostate cancer	5.37e-05	0.00028	CcSEcCtD
Pimecrolimus—Headache—Docetaxel—prostate cancer	5.34e-05	0.000279	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—prostate cancer	5.32e-05	0.000278	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—prostate cancer	5.32e-05	0.000278	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—prostate cancer	5.28e-05	0.000276	CcSEcCtD
Pimecrolimus—Vomiting—Capecitabine—prostate cancer	5.25e-05	0.000274	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.24e-05	0.000273	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—prostate cancer	5.22e-05	0.000272	CcSEcCtD
Pimecrolimus—Rash—Capecitabine—prostate cancer	5.2e-05	0.000271	CcSEcCtD
Pimecrolimus—Pruritus—Prednisone—prostate cancer	5.2e-05	0.000271	CcSEcCtD
Pimecrolimus—Dermatitis—Capecitabine—prostate cancer	5.2e-05	0.000271	CcSEcCtD
Pimecrolimus—Headache—Capecitabine—prostate cancer	5.17e-05	0.00027	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—prostate cancer	5.17e-05	0.00027	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—prostate cancer	5.16e-05	0.000269	CcSEcCtD
Pimecrolimus—Dyspnoea—Epirubicin—prostate cancer	5.12e-05	0.000267	CcSEcCtD
Pimecrolimus—Nausea—Docetaxel—prostate cancer	5.06e-05	0.000264	CcSEcCtD
Pimecrolimus—Diarrhoea—Prednisone—prostate cancer	5.03e-05	0.000262	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—prostate cancer	4.96e-05	0.000259	CcSEcCtD
Pimecrolimus—Constipation—Epirubicin—prostate cancer	4.92e-05	0.000257	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—prostate cancer	4.92e-05	0.000257	CcSEcCtD
Pimecrolimus—Nausea—Capecitabine—prostate cancer	4.9e-05	0.000256	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.85e-05	0.000253	CcSEcCtD
Pimecrolimus—Paraesthesia—Doxorubicin—prostate cancer	4.78e-05	0.000249	CcSEcCtD
Pimecrolimus—Dyspnoea—Doxorubicin—prostate cancer	4.74e-05	0.000247	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Epirubicin—prostate cancer	4.7e-05	0.000245	CcSEcCtD
Pimecrolimus—Vomiting—Prednisone—prostate cancer	4.67e-05	0.000244	CcSEcCtD
Pimecrolimus—Rash—Prednisone—prostate cancer	4.63e-05	0.000242	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisone—prostate cancer	4.63e-05	0.000242	CcSEcCtD
Pimecrolimus—Headache—Prednisone—prostate cancer	4.6e-05	0.00024	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.59e-05	0.00024	CcSEcCtD
Pimecrolimus—Urticaria—Epirubicin—prostate cancer	4.57e-05	0.000238	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—prostate cancer	4.55e-05	0.000237	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—prostate cancer	4.55e-05	0.000237	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—prostate cancer	4.54e-05	0.000237	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—prostate cancer	4.54e-05	0.000237	CcSEcCtD
Pimecrolimus—Nausea—Prednisone—prostate cancer	4.37e-05	0.000228	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—prostate cancer	4.35e-05	0.000227	CcSEcCtD
Pimecrolimus—Hypersensitivity—Epirubicin—prostate cancer	4.23e-05	0.000221	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—prostate cancer	4.23e-05	0.00022	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—prostate cancer	4.2e-05	0.000219	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—prostate cancer	4.2e-05	0.000219	CcSEcCtD
Pimecrolimus—Pruritus—Epirubicin—prostate cancer	4.07e-05	0.000212	CcSEcCtD
Pimecrolimus—Diarrhoea—Epirubicin—prostate cancer	3.93e-05	0.000205	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—prostate cancer	3.92e-05	0.000204	CcSEcCtD
Pimecrolimus—Pruritus—Doxorubicin—prostate cancer	3.76e-05	0.000196	CcSEcCtD
Pimecrolimus—Vomiting—Epirubicin—prostate cancer	3.65e-05	0.000191	CcSEcCtD
Pimecrolimus—Diarrhoea—Doxorubicin—prostate cancer	3.64e-05	0.00019	CcSEcCtD
Pimecrolimus—Rash—Epirubicin—prostate cancer	3.62e-05	0.000189	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—prostate cancer	3.62e-05	0.000189	CcSEcCtD
Pimecrolimus—Headache—Epirubicin—prostate cancer	3.6e-05	0.000188	CcSEcCtD
Pimecrolimus—Nausea—Epirubicin—prostate cancer	3.41e-05	0.000178	CcSEcCtD
Pimecrolimus—Vomiting—Doxorubicin—prostate cancer	3.38e-05	0.000176	CcSEcCtD
Pimecrolimus—Rash—Doxorubicin—prostate cancer	3.35e-05	0.000175	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—prostate cancer	3.35e-05	0.000175	CcSEcCtD
Pimecrolimus—Headache—Doxorubicin—prostate cancer	3.33e-05	0.000174	CcSEcCtD
Pimecrolimus—Nausea—Doxorubicin—prostate cancer	3.16e-05	0.000165	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—EP300—prostate cancer	1.14e-05	7e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAP3K7—prostate cancer	1.14e-05	6.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BAD—prostate cancer	1.14e-05	6.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.12e-05	6.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AMACR—prostate cancer	1.12e-05	6.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DEGS1—prostate cancer	1.12e-05	6.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAT1—prostate cancer	1.12e-05	6.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.12e-05	6.89e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAP2K1—prostate cancer	1.12e-05	6.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CAV1—prostate cancer	1.12e-05	6.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SRC—prostate cancer	1.11e-05	6.83e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CD—prostate cancer	1.11e-05	6.82e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SRC—prostate cancer	1.11e-05	6.8e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SERPINE1—prostate cancer	1.1e-05	6.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF10—prostate cancer	1.1e-05	6.72e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS1—prostate cancer	1.09e-05	6.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGF—prostate cancer	1.09e-05	6.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRB2—prostate cancer	1.08e-05	6.65e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.07e-05	6.57e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—prostate cancer	1.07e-05	6.56e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF2—prostate cancer	1.06e-05	6.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VAV3—prostate cancer	1.06e-05	6.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—GSK3B—prostate cancer	1.06e-05	6.48e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—prostate cancer	1.05e-05	6.44e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BAD—prostate cancer	1.05e-05	6.44e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFBR2—prostate cancer	1.04e-05	6.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ITPR1—prostate cancer	1.03e-05	6.29e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JAK2—prostate cancer	1.02e-05	6.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CREBBP—prostate cancer	1.02e-05	6.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—prostate cancer	1.02e-05	6.24e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APC—prostate cancer	1.02e-05	6.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—prostate cancer	1.01e-05	6.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGF—prostate cancer	1e-05	6.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS1—prostate cancer	1e-05	6.16e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MDM2—prostate cancer	9.96e-06	6.11e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—prostate cancer	9.94e-06	6.1e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—prostate cancer	9.91e-06	6.08e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—prostate cancer	9.82e-06	6.03e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1R—prostate cancer	9.81e-06	6.02e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—prostate cancer	9.76e-06	5.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GSK3B—prostate cancer	9.75e-06	5.98e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAP2K1—prostate cancer	9.74e-06	5.97e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—prostate cancer	9.72e-06	5.96e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CB—prostate cancer	9.69e-06	5.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CD—prostate cancer	9.67e-06	5.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—INS—prostate cancer	9.62e-06	5.9e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—prostate cancer	9.6e-06	5.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPGD—prostate cancer	9.55e-06	5.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—B4GALT4—prostate cancer	9.55e-06	5.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CREBBP—prostate cancer	9.42e-06	5.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LPL—prostate cancer	9.4e-06	5.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDGFRB—prostate cancer	9.32e-06	5.72e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—prostate cancer	9.31e-06	5.71e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF2—prostate cancer	9.26e-06	5.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—prostate cancer	9.22e-06	5.66e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—prostate cancer	9.18e-06	5.63e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1B—prostate cancer	9.1e-06	5.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ITGB3—prostate cancer	9.08e-06	5.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAP2K1—prostate cancer	8.99e-06	5.52e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TNFRSF21—prostate cancer	8.98e-06	5.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CD—prostate cancer	8.93e-06	5.48e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—prostate cancer	8.91e-06	5.47e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—prostate cancer	8.9e-06	5.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—JAK2—prostate cancer	8.88e-06	5.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SERPINE1—prostate cancer	8.83e-06	5.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—prostate cancer	8.82e-06	5.41e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB3—prostate cancer	8.81e-06	5.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR2—prostate cancer	8.8e-06	5.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—prostate cancer	8.79e-06	5.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP7B1—prostate cancer	8.73e-06	5.36e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTAP—prostate cancer	8.73e-06	5.36e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—prostate cancer	8.68e-06	5.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MDM2—prostate cancer	8.67e-06	5.32e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNB1—prostate cancer	8.59e-06	5.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF2—prostate cancer	8.55e-06	5.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—prostate cancer	8.54e-06	5.24e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SULT1E1—prostate cancer	8.51e-06	5.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SRD5A1—prostate cancer	8.51e-06	5.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—prostate cancer	8.47e-06	5.2e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—prostate cancer	8.44e-06	5.18e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—prostate cancer	8.44e-06	5.18e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—prostate cancer	8.43e-06	5.17e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CB—prostate cancer	8.43e-06	5.17e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—prostate cancer	8.42e-06	5.17e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1A—prostate cancer	8.39e-06	5.15e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—prostate cancer	8.37e-06	5.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—JAK2—prostate cancer	8.2e-06	5.03e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACSL4—prostate cancer	8.12e-06	4.98e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD17B3—prostate cancer	8.12e-06	4.98e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—prostate cancer	8.07e-06	4.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MDM2—prostate cancer	8e-06	4.91e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EP300—prostate cancer	7.99e-06	4.9e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1B—prostate cancer	7.91e-06	4.85e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—prostate cancer	7.89e-06	4.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LEP—prostate cancer	7.88e-06	4.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—prostate cancer	7.81e-06	4.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CAV1—prostate cancer	7.81e-06	4.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CB—prostate cancer	7.78e-06	4.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PHGDH—prostate cancer	7.78e-06	4.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UMPS—prostate cancer	7.78e-06	4.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ARG2—prostate cancer	7.78e-06	4.78e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SRC—prostate cancer	7.77e-06	4.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—prostate cancer	7.74e-06	4.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—prostate cancer	7.72e-06	4.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—prostate cancer	7.71e-06	4.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LDHB—prostate cancer	7.63e-06	4.68e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—prostate cancer	7.56e-06	4.64e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ESR1—prostate cancer	7.53e-06	4.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP3A5—prostate cancer	7.49e-06	4.6e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—prostate cancer	7.49e-06	4.6e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTNNB1—prostate cancer	7.47e-06	4.59e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—prostate cancer	7.47e-06	4.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BAD—prostate cancer	7.35e-06	4.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1B—prostate cancer	7.3e-06	4.48e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1A—prostate cancer	7.3e-06	4.48e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—prostate cancer	7.29e-06	4.47e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PDHA1—prostate cancer	7.24e-06	4.44e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UCP3—prostate cancer	7.24e-06	4.44e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TCN2—prostate cancer	7.24e-06	4.44e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA3—prostate cancer	7.24e-06	4.44e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—prostate cancer	7.21e-06	4.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APC—prostate cancer	7.11e-06	4.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—prostate cancer	7.11e-06	4.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGF—prostate cancer	7.03e-06	4.31e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS1—prostate cancer	7.03e-06	4.31e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—prostate cancer	6.96e-06	4.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EP300—prostate cancer	6.95e-06	4.26e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—prostate cancer	6.94e-06	4.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—prostate cancer	6.92e-06	4.25e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD3B1—prostate cancer	6.9e-06	4.24e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC22A3—prostate cancer	6.9e-06	4.24e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CTNNB1—prostate cancer	6.9e-06	4.23e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—prostate cancer	6.89e-06	4.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GSK3B—prostate cancer	6.83e-06	4.19e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—prostate cancer	6.81e-06	4.18e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SRC—prostate cancer	6.76e-06	4.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1A—prostate cancer	6.74e-06	4.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INS—prostate cancer	6.73e-06	4.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—prostate cancer	6.73e-06	4.13e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TBXAS1—prostate cancer	6.62e-06	4.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA4—prostate cancer	6.62e-06	4.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CREBBP—prostate cancer	6.6e-06	4.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—prostate cancer	6.52e-06	4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—prostate cancer	6.51e-06	4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA2—prostate cancer	6.45e-06	3.96e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—prostate cancer	6.43e-06	3.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EP300—prostate cancer	6.41e-06	3.94e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCG5—prostate cancer	6.37e-06	3.91e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SULT1A1—prostate cancer	6.37e-06	3.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAP2K1—prostate cancer	6.3e-06	3.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CD—prostate cancer	6.25e-06	3.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SRC—prostate cancer	6.24e-06	3.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA1—prostate cancer	6.22e-06	3.82e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SERPINE1—prostate cancer	6.19e-06	3.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD3B2—prostate cancer	6.15e-06	3.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTO1—prostate cancer	6.15e-06	3.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAT2—prostate cancer	6.15e-06	3.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—prostate cancer	6.02e-06	3.69e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF2—prostate cancer	5.99e-06	3.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—prostate cancer	5.92e-06	3.63e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—prostate cancer	5.91e-06	3.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—prostate cancer	5.91e-06	3.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLCB2—prostate cancer	5.9e-06	3.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LRP2—prostate cancer	5.9e-06	3.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2C18—prostate cancer	5.9e-06	3.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—P4HB—prostate cancer	5.78e-06	3.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JAK2—prostate cancer	5.74e-06	3.52e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—prostate cancer	5.72e-06	3.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC22A1—prostate cancer	5.63e-06	3.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MDM2—prostate cancer	5.6e-06	3.44e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—prostate cancer	5.59e-06	3.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—prostate cancer	5.59e-06	3.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—prostate cancer	5.58e-06	3.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—prostate cancer	5.52e-06	3.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SULT2A1—prostate cancer	5.48e-06	3.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—prostate cancer	5.47e-06	3.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CB—prostate cancer	5.45e-06	3.34e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MED12—prostate cancer	5.4e-06	3.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNG5—prostate cancer	5.35e-06	3.28e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—prostate cancer	5.24e-06	3.21e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—prostate cancer	5.23e-06	3.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—prostate cancer	5.16e-06	3.17e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA3—prostate cancer	5.16e-06	3.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—prostate cancer	5.14e-06	3.15e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1B—prostate cancer	5.12e-06	3.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—prostate cancer	5.01e-06	3.08e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—prostate cancer	5.01e-06	3.07e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPGDS—prostate cancer	4.92e-06	3.02e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2C19—prostate cancer	4.89e-06	3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—prostate cancer	4.88e-06	2.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNB1—prostate cancer	4.83e-06	2.96e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—prostate cancer	4.83e-06	2.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACHE—prostate cancer	4.77e-06	2.93e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTT1—prostate cancer	4.77e-06	2.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—prostate cancer	4.75e-06	2.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—prostate cancer	4.74e-06	2.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1A—prostate cancer	4.72e-06	2.9e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.72e-06	2.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—prostate cancer	4.71e-06	2.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.59e-06	2.81e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PRKACB—prostate cancer	4.56e-06	2.8e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—prostate cancer	4.55e-06	2.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.52e-06	2.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EP300—prostate cancer	4.49e-06	2.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SRC—prostate cancer	4.37e-06	2.68e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA2—prostate cancer	4.3e-06	2.64e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—prostate cancer	4.25e-06	2.61e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—prostate cancer	4.21e-06	2.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—prostate cancer	4.2e-06	2.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—prostate cancer	4.2e-06	2.58e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.11e-06	2.52e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.01e-06	2.46e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NQO1—prostate cancer	3.96e-06	2.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—prostate cancer	3.91e-06	2.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TH—prostate cancer	3.91e-06	2.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—prostate cancer	3.9e-06	2.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—prostate cancer	3.88e-06	2.38e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—prostate cancer	3.83e-06	2.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.8e-06	2.33e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GGT1—prostate cancer	3.68e-06	2.26e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA1—prostate cancer	3.63e-06	2.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—prostate cancer	3.62e-06	2.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.57e-06	2.19e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RXRA—prostate cancer	3.45e-06	2.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—prostate cancer	3.32e-06	2.04e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COMT—prostate cancer	3.32e-06	2.04e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTP1—prostate cancer	3.31e-06	2.03e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ITPR1—prostate cancer	3.25e-06	2e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—prostate cancer	3.21e-06	1.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMS—prostate cancer	3.07e-06	1.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—prostate cancer	3.04e-06	1.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPL—prostate cancer	2.98e-06	1.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—prostate cancer	2.94e-06	1.81e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.88e-06	1.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ERCC2—prostate cancer	2.86e-06	1.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—prostate cancer	2.71e-06	1.67e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—prostate cancer	2.69e-06	1.65e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARA—prostate cancer	2.63e-06	1.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAV1—prostate cancer	2.48e-06	1.52e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.26e-06	1.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—INS—prostate cancer	2.14e-06	1.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CREBBP—prostate cancer	2.09e-06	1.28e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.98e-06	1.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—prostate cancer	1.87e-06	1.15e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.73e-06	1.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—prostate cancer	1.71e-06	1.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—prostate cancer	1.49e-06	9.17e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—EP300—prostate cancer	1.42e-06	8.74e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.05e-06	6.47e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—prostate cancer	8.61e-07	5.28e-06	CbGpPWpGaD
